Clinical Trial Update: A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. [Phase 3]

View source ↗

Summary

Phase 3 trial update on ARGX-113 in generalized myasthenia gravis reports safety and tolerability findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• ARGX-113

Snippet

Sponsor: argenx | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: COMPLETED | Results posted: 2023-07-14